|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma.
|
24852187 |
2014 |
|
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
On multivariable analyses, subtype changes were more common in high-grade breast cancer (P < 0.001; OR, 1.077; 95% CI, 1.031-1.113) and CEA ≥ 5 (P = 0.032; OR, 2.658; 95% CI, 1.088-6.490).
|
31742206 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The expression of the CEACAM19 gene, a novel member of the CEA family, is associated with breast cancer progression.
|
23525470 |
2013 |
|
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Additionally, the tumor markers for breast cancer (CA 15-3 and CEA) were analyzed in both groups.
|
31412345 |
2019 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To construct a pRNA-bipHRE-CEA vector, the carcinoma embryonic antigen (CEA) promoter designed in two directions and the vascular endothelial growth factor (VEGF) enhancer were inserted between two promoters for hypoxic cancer specific gene expression.
|
29656061 |
2018 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
At multivariate analysis, cancer-related survival was associated with Dukes' stage (p<0.0001), CEA level (p=0.02), and mutant circulating KRAS2 (p=0.01).
|
17177160 |
2007 |
|
Malignant tumor of colon
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ROC curve showed that miR-125a-3p abundant level may predict colon cancer with an area of under the curve (AUC) of 68.5%, in comparison to that of CEA at 83.6%.
|
28646161 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
An area under the curve (AUC) for NSCLC resulting from sB7-H4 (0.863), which was significantly better than any other tumour markers tested including CA125 (0.763), and CEA (0.775).
|
27216449 |
2018 |
|
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Further verification confirmed the elevated plasma BST2 levels in CRC patients (2.35 ± 0.13 ng/mL) versus controls (1.04 ± 0.03 ng/mL) (p < 0.01), with an area under the ROC curve (AUC) being 0.858 comparable to that of CEA (0.867).
|
26494939 |
2015 |
|
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Comparison of two CEA assays in primary and recurrent large bowel carcinoma with different DNA ploidy pattern.
|
3816909 |
1986 |
|
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients who have undergone curative resection for primary colorectal cancer are typically followed up with scheduled CEA testing for 5 years.
|
28282381 |
2017 |
|
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<i>TP53, KRAS, APC</i>) has limited diagnostic sensitivity (40-60%), however, methylated DNA including <i>SEPT9, SFRP1, SDC2</i> can be applied with higher sensitivity (up to 90%) for CRC.Circulating miRNAs (e.g. miR-21, miR-92, miR-141) provide comparably high sensitivity for CRC as the circulating tumor cell mRNA markers (e.g.EGFR, CK19, CK20, CEA).
|
31046485 |
2019 |
|
Neoplasm Metastasis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
According to the multivariate analysis, two factors were independently predictive of the poor OS: >2 regions of metastasis (relative risk [RR], 2.6; 95% CI, 1.3-5.4) and a high level of carcinoembryonic antigen [CEA] (RR, 3.4; 95% CI, 1.6-7.4).
|
28941466 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In a multicenter study, a total of 196 peripheral blood samples were collected from 76 patients with tumor stage Dukes' A to D and analyzed using a DTC detection assay consisting of immunomagnetic selection and expression analysis of the tumor-associated genes CEA, EGFR and GA733-2.
|
17649779 |
2007 |
|
Secondary malignant neoplasm of liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The in vivo VDEPT experiment with RCM-1 and the adenovirus vector driven by the CEA promoter revealed attenuation of liver metastases in the treatment group.
|
12783317 |
2003 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Additionally, the tumor markers for breast cancer (CA 15-3 and CEA) were analyzed in both groups.
|
31412345 |
2019 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
On multivariable analyses, subtype changes were more common in high-grade breast cancer (P < 0.001; OR, 1.077; 95% CI, 1.031-1.113) and CEA ≥ 5 (P = 0.032; OR, 2.658; 95% CI, 1.088-6.490).
|
31742206 |
2019 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The expression of the CEACAM19 gene, a novel member of the CEA family, is associated with breast cancer progression.
|
23525470 |
2013 |
|
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multivariate competing risk analysis showed that age (SHR, 1.72; 95% CI, 1.10-2.83, p = 0.031), CEA (SHR, 1.94; 95% CI, 1.09-3.46, p = 0.024), pT4 (SHR, 2.77; 95% CI, 1.01-7.57, p = 0.047), lymph node metastasis (SHR 1.92, 95% CI: 1.09-3.38, p = 0.024) and LVI (SHR, 1.84; 95% CI, 1.06-3.20, p = 0.028) were independent risk factors for LRR (all p < 0.05).
|
31315683 |
2019 |
|
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A higher RDW was significantly associated with older age, a larger tumor diameter, deeper tumor infiltration, and lymph node metastasis while a lower PDW was significantly associated with male, older age, a larger tumor diameter, deeper tumor infiltration, elevated CEA and CA125.
|
29262773 |
2017 |
|
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A-kinase-interacting protein 1 expression was elevated in tumor tissue compared with paired adjacent tissue (P < .001), and high AKIP1 tumor tissue expression was correlated with poor pathological differentiation (P < .001), tumor size >5 cm (P = .001), lymph node metastasis (P = .016), higher TNM stages (P < .001), and abnormal CEA level (>5 ng/mL) (P = .035).
|
31782840 |
2019 |
|
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ROC curve showed that miR-125a-3p abundant level may predict colon cancer with an area of under the curve (AUC) of 68.5%, in comparison to that of CEA at 83.6%.
|
28646161 |
2017 |
|
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
At multivariate analysis, cancer-related survival was associated with Dukes' stage (p<0.0001), CEA level (p=0.02), and mutant circulating KRAS2 (p=0.01).
|
17177160 |
2007 |
|
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To construct a pRNA-bipHRE-CEA vector, the carcinoma embryonic antigen (CEA) promoter designed in two directions and the vascular endothelial growth factor (VEGF) enhancer were inserted between two promoters for hypoxic cancer specific gene expression.
|
29656061 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although many studies on CEA promoter and ST13 gene were reported but no construct has been performed to combine both of them as a new strategy for colorectal cancer (CRC) specific therapy.
|
23077639 |
2012 |